{"id":72,"date":"2026-01-06T10:06:00","date_gmt":"2026-01-06T10:06:00","guid":{"rendered":"https:\/\/www.nextpayglobal.com\/blog\/?p=72"},"modified":"2026-05-01T17:40:49","modified_gmt":"2026-05-01T17:40:49","slug":"life-sciences-florida-fx-guide","status":"publish","type":"post","link":"https:\/\/www.nextpayglobal.com\/blog\/life-sciences-florida-fx-guide\/","title":{"rendered":"Life Sciences & MedTech Companies: Managing FX When You Enter the US"},"content":{"rendered":"\n
\"life
FX and cross-border payment solutions for life sciences and MedTech companies entering the US market.<\/figcaption><\/figure>\n\n\n\n

Florida is home to approximately 6,700 life sciences Florida companies employing around 100,000 people \u2014 and the sector is growing. For European and international life sciences and MedTech businesses establishing US operations, Florida offers a compelling combination of research infrastructure, clinical trial networks, and access to the world’s largest healthcare market.<\/p>\n\n\n\n

But the financial complexity of international life sciences operations is significant. Clinical trial payments, R&D reimbursements, regulatory fees, equipment procurement from global suppliers, and profit repatriation all create multi-currency exposure that, if unmanaged, erodes margins that are already under pressure in a capital-intensive sector.<\/p>\n\n\n\n

The FX challenges specific to life sciences and MedTech<\/h3>\n\n\n\n

Clinical trial and research payments<\/h4>\n\n\n\n

Multi-site clinical trials frequently involve payments across five to fifteen jurisdictions simultaneously \u2014 investigators, CROs, IRBs, and patient recruitment vendors in multiple countries and currencies. Managing these through a standard bank account means multiple wire fees, retail FX spreads on every conversion, and no visibility over the total currency exposure of a single trial.<\/p>\n\n\n\n

Equipment and supply chain payments<\/h4>\n\n\n\n

Medical device manufacturers and diagnostics companies typically source components, materials, and specialist equipment from global suppliers. A company manufacturing in Florida but sourcing precision parts from Germany, Switzerland, or Japan has ongoing EUR, CHF, and JPY exposure that needs active management rather than ad-hoc conversion.<\/p>\n\n\n\n

Regulatory and licensing fees<\/h4>\n\n\n\n

FDA submission fees, patent filings, and international regulatory compliance costs are denominated in USD for US operations but often must be funded from non-USD accounts. The timing of these payments can also be inflexible \u2014 you cannot delay an FDA filing because the exchange rate is unfavourable.<\/p>\n\n\n\n

Repatriation of US revenue<\/h4>\n\n\n\n

For companies whose US subsidiary generates USD revenue but whose parent entity holds costs in GBP, EUR, or another currency, the repatriation decision is a recurring FX event. Made poorly \u2014 reactively, at market rates, without forward planning \u2014 it introduces unnecessary volatility into reported earnings.<\/p>\n\n\n\n

Three FX principles for life sciences companies entering the US<\/h3>\n\n\n\n